Report Sections

See All Reports

Coronavirus Infections (840) Severe Acute Respiratory Syndrome (575) Infection (491) Pneumonia (381) Communicable Diseases (217) Respiratory Distress Syndrome, Adult (187) Acute Lung Injury (148) Respiratory Distress Syndrome, Newborn (148) (134) Syndrome (129) Virus Diseases (98) Depression (92) Pneumonia, Viral (81) Critical Illness (69) Anxiety Disorders (57) Neoplasms (47) Respiratory Tract Infections (46) Disease (41) Diabetes Mellitus (39) Cardiovascular Diseases (38) Stress Disorders, Post-Traumatic (38) Emergencies (36) Wounds and Injuries (36) Depressive Disorder (35) Inflammation (35) Lung Diseases (33) Stress Disorders, Traumatic (33) Stress, Psychological (33) Respiratory Tract Diseases (31) Hypoxia (30) Lung Injury (30) Acute Kidney Injury (29) Mental Disorders (29) Thrombosis (29) Influenza, Human (27) Hypertension (25) Respiration Disorders (23) Disease Progression (22) Fibrosis (22) Cognitive Dysfunction (21) Olfaction Disorders (21) Arthritis (20) Diabetes Mellitus, Type 2 (20) Sclerosis (20) Burnout, Psychological (19) Multiple Sclerosis (19) Pulmonary Disease, Chronic Obstructive (19) Respiratory Aspiration (19) Thromboembolism (19) Embolism (18) Lung Diseases, Obstructive (18) Pulmonary Fibrosis (18) HIV Infections (17) Kidney Diseases (17) Stroke (17) Blood Coagulation Disorders (16) Heart Failure (16) Hemostatic Disorders (16) Pulmonary Embolism (16) Arthritis, Rheumatoid (15) Asthma (15) Chronic Disease (15) Heart Diseases (15) Lung Diseases, Interstitial (15) Lung Neoplasms (15) Myocardial Infarction (15) Substance-Related Disorders (15) Autism Spectrum Disorder (14) Chronic Pain (14) Crohn Disease (14) Brain Injuries (13) Diabetes Mellitus, Type 1 (13) Infarction (13) Venous Thrombosis (12) Autistic Disorder (11) Carcinoma (11) Colitis (11) Colitis, Ulcerative (11) Dyspnea (11) Feeding and Eating Disorders (11) Obesity (11) Rheumatic Diseases (11) Ulcer (11) Alzheimer Disease (10) Burnout, Professional (10) Leukemia (10) Lymphoma (10) Myocarditis (10) Overweight (10) Parkinson Disease (10) Pregnancy Complications (10) Renal Insufficiency, Chronic (10) Respiratory Syncytial Virus Infections (10) Sepsis (10) Brain Injuries, Traumatic (9) Collagen Diseases (9) Coronary Artery Disease (9) Cystic Fibrosis (9) Dementia (9) Depression, Postpartum (9) Frailty (9) Inflammatory Bowel Diseases (9) Liver Diseases (9) Musculoskeletal Pain (9) Pneumonia, Ventilator-Associated (9) Pulmonary Valve Insufficiency (9) Renal Insufficiency (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Weight Loss (9) Alcohol Drinking (8) Alcoholism (8) Hematologic Neoplasms (8) Infertility (8) Ischemia (8) Parasomnias (8) Problem Behavior (8) Psychotic Disorders (8) RNA Virus Infections (8) Breast Neoplasms (7) Convalescence (7) Coronary Disease (7) Dyssomnias (7) Fatigue (7) Metabolic Syndrome (7) Migraine Disorders (7) Myocardial Ischemia (7) Neoplasm Metastasis (7) Psoriasis (7) Schizophrenia (7) Shock (7) Spinal Cord Injuries (7) Toxemia (7) Acute Coronary Syndrome (6) Brain Diseases (6) Bronchiectasis (6) Carcinoma, Non-Small-Cell Lung (6) Child Development Disorders, Pervasive (6) Colorectal Neoplasms (6) Deglutition Disorders (6) Delirium (6) Disease Susceptibility (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Kidney Failure, Chronic (6) Lupus Erythematosus, Systemic (6) Lymphopenia (6) Multiple Organ Failure (6) Neurologic Manifestations (6) Osteoarthritis (6) (6) Pediatric Obesity (6) Prostatic Neoplasms (6) Sleep Apnea Syndromes (6) Sleep Apnea, Obstructive (6) Appendicitis (5) Arthritis, Psoriatic (5) Autoimmune Diseases (5) Coronaviridae Infections (5) Cross Infection (5) Depressive Disorder, Major (5) Dermatitis (5) Disseminated Intravascular Coagulation (5) Fibromyalgia (5) Gastroparesis (5) Head and Neck Neoplasms (5) Hypersensitivity (5) Idiopathic Pulmonary Fibrosis (5) Leukemia, Lymphoid (5) Metabolic Diseases (5) Mobility Limitation (5) Nervous System Diseases (5) Occupational Stress (5) Osteoarthritis, Knee (5) Pancreatic Neoplasms (5) Premature Birth (5) Triple Negative Breast Neoplasms (5) Acquired Immunodeficiency Syndrome (4) Acute Disease (4) Adenoviridae Infections (4) Amyotrophic Lateral Sclerosis (4) Anemia, Sickle Cell (4) Arrhythmias, Cardiac (4) Asymptomatic Diseases (4) Atrial Fibrillation (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Carcinoma, Renal Cell (4) Cognition Disorders (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Dermatitis, Atopic (4) Digestive System Diseases (4) Eczema (4) Embolism and Thrombosis (4) Endometriosis (4) Gastrointestinal Diseases (4) Headache (4) Heart Arrest (4) Hematologic Diseases (4) Hemophilia A (4) Hemorrhage (4) Hypertension, Pulmonary (4) Intestinal Diseases (4) Liver Cirrhosis (4) Macular Degeneration (4) Malnutrition (4) Motor Neuron Disease (4) (4) Mycobacterium Infections (4) Panic Disorder (4) Peripheral Arterial Disease (4) Postoperative Complications (4) Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Initiation and Maintenance Disorders (4) Spondylarthritis (4) Systemic Inflammatory Response Syndrome (4) Thrombophilia (4) Tobacco Use Disorder (4) Vascular Diseases (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Apnea (3) Bacteremia (3) Bacterial Infections (3) Bulimia (3) Cardiomyopathies (3) Celiac Disease (3) Cerebral Palsy (3) Chilblains (3) Common Cold (3) Congenital Abnormalities (3) Developmental Disabilities (3) Dysgeusia (3) Endocrine System Diseases (3) Eye Diseases (3) Fatigue Syndrome, Chronic (3) Fatty Liver (3) Fever (3) Fistula (3) Fractures, Bone (3) Ganglion Cysts (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Heart Defects, Congenital (3) Hepatitis C (3) Huntington Disease (3) Hyperglycemia (3) Hypothermia (3) Kidney Calculi (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Leukemia, Myeloid, Acute (3) Macular Edema (3) Measles (3) Melanoma (3) Meningitis (3) Mouth Diseases (3) Mucocutaneous Lymph Node Syndrome (3) Multiple Myeloma (3) Multiple Sclerosis, Relapsing-Remitting (3) Myelodysplastic Syndromes (3) Myeloproliferative Disorders (3) Neoplasms, Plasma Cell (3) Neuroendocrine Tumors (3) Non-alcoholic Fatty Liver Disease (3) Obesity, Morbid (3) Obstetric Labor, Premature (3) Ovarian Neoplasms (3) Paramyxoviridae Infections (3) Peripheral Nervous System Diseases (3) Peripheral Vascular Diseases (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psychological Trauma (3) Pulmonary Edema (3) Rare Diseases (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Seizures (3) Shock, Septic (3) Sleep Wake Disorders (3) Small Cell Lung Carcinoma (3) Suicidal Ideation (3) Tachycardia (3) Taste Disorders (3) Tuberculosis (3) Ageusia (2) Agoraphobia (2) Alcoholic Intoxication (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Angina Pectoris (2) Anxiety, Separation (2) Aortic Valve Stenosis (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrophy (2) Back Pain (2) Behcet Syndrome (2) Binge-Eating Disorder (2) Bipolar Disorder (2) Bronchitis (2) Bronchitis, Chronic (2) Bronchopulmonary Dysplasia (2) Caliciviridae Infections (2) Carcinoma, Small Cell (2) Carcinoma, Squamous Cell (2) Cataract (2) Cholangitis (2) Clinical Deterioration (2) Clostridium Infections (2) Communicable Diseases, Emerging (2) Communication Disorders (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Conjunctivitis (2) Depressive Disorder, Treatment-Resistant (2) Diabetic Nephropathies (2) Diabetic Neuropathies (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Emphysema (2) Endocarditis (2) Epilepsy (2) Facies (2) Fractures, Stress (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Genetic Predisposition to Disease (2) Glioblastoma (2) Gout (2) Healthcare-Associated Pneumonia (2) Heart Failure, Systolic (2) Hepatitis (2) Hepatitis A (2) Humeral Fractures (2) Hyperkinesis (2) Hyperphagia (2) Hyperplasia (2) Hypertension, Pregnancy-Induced (2) Hypotension (2) Hypoventilation (2) Infertility, Male (2) Intervertebral Disc Degeneration (2) Ischemic Attack, Transient (2) Jaundice (2) Joint Diseases (2) Leukemia, Myeloid (2) Low Back Pain (2) Lymphedema (2) Lymphoma, B-Cell (2) Lymphoma, Mantle-Cell (2) Lymphoproliferative Disorders (2) Meningitis, Meningococcal (2) Mood Disorders (2) Mucositis (2) Muscle Spasticity (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myofascial Pain Syndromes (2) Myositis (2) Necrosis (2) Nephrolithiasis (2) Nerve Degeneration (2) Neurocognitive Disorders (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Oropharyngeal Neoplasms (2) Pain (2) Pain, Postoperative (2) Pancreatitis (2) Paresis (2) Periodontal Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Bacterial (2) Pneumonia, Pneumocystis (2) Pre-Eclampsia (2) Preleukemia (2) Pulmonary Eosinophilia (2) Purpura, Thrombocytopenic, Idiopathic (2) Recurrence (2) Respiratory Sounds (2) Rupture (2) Sarcoidosis (2) Sarcopenia (2) (2) Scleroderma, Systemic (2) Spinal Diseases (2) Sprains and Strains (2) Squamous Cell Carcinoma of Head and Neck (2) Stillbirth (2) Stomatitis (2) Suicide (2) Temporomandibular Joint Disorders (2) Temporomandibular Joint Dysfunction Syndrome (2) Thoracic Diseases (2) Thrombocytopenia (2) Thyroid Diseases (2) Trauma and Stressor Related Disorders (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Wet Macular Degeneration (2) Yellow Fever (2) Abortion, Spontaneous (1) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Aggression (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Altitude Sickness (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia (1) Anemia, Aplastic (1) Anemia, Iron-Deficiency (1) Aneurysm (1) Aneurysm, Ruptured (1) Angina, Stable (1) Angioedema (1) Angioedemas, Hereditary (1) Ankle Fractures (1) Anorexia (1) Anorexia Nervosa (1) Arachnoiditis (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Autonomic Nervous System Diseases (1) Barotrauma (1) Biliary Tract Neoplasms (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bone Marrow Diseases (1) Bradycardia (1) Brain Concussion (1) Brain Neoplasms (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Brucellosis (1) Bruxism (1) Bulimia Nervosa (1) (1) Calculi (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Carcinoma, Ovarian Epithelial (1) Cardiotoxicity (1) Cardiovascular Abnormalities (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chorea (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Colitis, Ulcerativ (1) Colonic Diseases (1) (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronary Restenosis (1) Coronary Stenosis (1) (1) Coronavirus Infect (1) Cough (1) Coxsackievirus Infections (1) Crohn Dise (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dehydration (1) Dental Calculus (1) Dental Plaque (1) DiGeorge Syndrome (1) Diabetic Foot (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Drug Overdose (1) Dry Eye Syndromes (1) Dysentery, Bacillary (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) Eclampsia (1) Emergence Delirium (1) Encephalitis (1) Endophthalmitis (1) Endotoxemia (1) Enterocolitis (1) Enterocolitis, Pseudomembranous (1) Enuresis (1) Eosinophilic Esophagitis (1) Epstein-Barr Virus Infections (1) Escherichia coli Infections (1) Esophageal Fistula (1) Esophageal and Gastric Varices (1) Esophagitis (1) Esophagitis, Peptic (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Food Hypersensitivity (1) Foot Ulcer (1) Fractures, Closed (1) Gait Disorders, Neurologic (1) Gambling (1) Gastrointestinal Stromal Tumors (1) Gaucher Disease (1) Genetic Diseases, Inborn (1) Geographic Atrophy (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Glomerulonephritis, IGA (1) Glomerulonephritis, Membranous (1) Guillain-Barre Syndrome (1) Halitosis (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis B (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Hodgkin Disease (1) Hot Flashes (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperkalemia (1) Hyperphosphatemia (1) Hypersensitivity, Immediate (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Iatrogenic Disease (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infecti (1) Infectious Mononucleosis (1) Infertility, Female (1) Intellectual Disability (1) Intermittent Claudication (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Keratoconjunctivitis (1) Keratoconjunctivitis Sicca (1) Keratosis (1) Keratosis, Actinic (1) Language Disorders (1) Leishmaniasis (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Leukemia, Prolymphocytic (1) Leukemia, Prolymphocytic, T-Cell (1) Lichen Sclerosus et Atrophicus (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Lung Ne (1) Lyme Disease (1) Lymphocytosis (1) Lymphoma, Large B-Cell, Diffuse (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) May-Thurner Syndrome (1) Memory Disorders (1) Meningococcal Infections (1) Meningomyelocele (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth, Edentulous (1) Movement Disorders (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myelodysplastic-Myeloproliferative Diseases (1) Myocardial Reperfusion Injury (1) Nasal Polyps (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplasms, Germ Cell and Embryonal (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Neurobehavioral Manifestations (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Oligospermia (1) Opioid-Related Disorders (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis (1) Otitis Media (1) Otitis Media with Effusion (1) Overwei (1) Pain, Intractable (1) Pain, Procedural (1) Papillomavirus Infections (1) Paraproteinemias (1) Parkin (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Pocket (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pneumon (1) Polyps (1) Pregnancy in Diabetics (1) Presbyopia (1) Primary Dysautonomias (1) Primary Myelofibrosis (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Protein-Energy Malnutrition (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Heart Disease (1) Rabies (1) Radiculopathy (1) Rectal Fistula (1) Rectal Neoplasms (1) Reperfusion Injury (1) Resp (1) Respiratory Distre (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Restless Legs Syndrome (1) Retinal Vein Occlusion (1) Rhinitis (1) Rhinitis, Allergic (1) Rhinitis, Allergic, Seasonal (1) Sarcoma (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) Scleroderma, Localized (1) (1) Self-Injurious Behavior (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Shoulder Fractures (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Speech Sound Disorder (1) Spina Bifida Cystica (1) Spinal Cord Diseases (1) Spinal Dysraphism (1) Spinal Stenosis (1) Spondylitis (1) Spondylitis, Ankylosing (1) Spondylolisthesis (1) Status Epilepticus (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Synovial Cyst (1) Tachycardia, Sinus (1) Tachycardia, Supraventricular (1) Tachycardia, Ventricular (1) Tachypnea (1) Thalassemia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tissue Adhesions (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Meningeal (1) Tuberculosis, Pulmonary (1) Urinary Bladder Neoplasms (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urogenital Neoplasms (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Venous Insufficiency (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Von Willebrand Diseases (1) Vulvar Lichen Sclerosus (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D001249: Asthma

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (39)


Name (Synonyms) Correlation
drug790 COVID Convalescent Plasma Wiki 0.37
drug795 COVID-19 Wiki 0.35
drug781 COVI-GUARD Wiki 0.26
Name (Synonyms) Correlation
drug778 CORVax Wiki 0.26
drug3966 Short acting beta agonist (SABA) (rescue medication) Wiki 0.26
drug782 COVI-VAC Wiki 0.26
drug792 COVID Watch Wiki 0.26
drug3468 QMF149 Wiki 0.26
drug780 COVI-AMG Wiki 0.26
drug776 CONVALESCENT PLASMA Wiki 0.26
drug5002 insurance navigation Wiki 0.26
drug404 Asthma reliever therapies Wiki 0.26
drug1010 Cliniporator Wiki 0.26
drug2674 Montelukast Oral Granules Wiki 0.26
drug1854 Health Promotion Program with cartoon education for Children with Asthma Wiki 0.26
drug787 COVID 19 diagnostic test by PCR Wiki 0.26
drug4710 Voriconazole Inhalation Powder Wiki 0.26
drug589 Best Standard of Care Wiki 0.26
drug2671 Monodose RS01 Wiki 0.26
drug4712 WEB BASED EDUCATION Wiki 0.26
drug2664 Mometasone furoate Wiki 0.26
drug403 Asthma controller therapies (incl. prednisone/prednisolone) Wiki 0.26
drug796 COVID-19 Androgen Sensitivity Test (CoVAST) Wiki 0.26
drug785 COVID 19 Diagnostic Test Wiki 0.26
drug5162 pulse oximeter Wiki 0.26
drug3737 Run-in medications (ICS-LABA combination) Wiki 0.26
drug1761 GSK3923868 Wiki 0.26
drug590 Best Standard of Care + CARDIO Wiki 0.26
drug2578 Mepolizumab 100 MG [Nucala] Wiki 0.26
drug1388 Dupilumab (SAR231893/REGN668) Wiki 0.26
drug4147 Standart Care given during normal examination Wiki 0.26
drug173 AZD1402 Wiki 0.26
drug773 COM-COVID anonimous survey Wiki 0.26
drug2033 IL-12 plasmid Wiki 0.26
drug4363 Tezepelumab Wiki 0.18
drug2453 MEDI3506 Wiki 0.15
drug2528 Matching placebo Wiki 0.13
drug3195 Placebo Wiki 0.07
drug4102 Standard of Care Wiki 0.04

Correlated MeSH Terms (12)


Name (Synonyms) Correlation
D011657 Pulmonary Eosinophilia NIH 0.37
D001982 Bronchial Diseases NIH 0.26
D006969 Hypersensitivity, Immediate NIH 0.26
Name (Synonyms) Correlation
D012130 Respiratory Hypersensitivity NIH 0.26
D053120 Respiratory Aspiration NIH 0.12
D006967 Hypersensitivity, NIH 0.12
D007154 Immune System Diseases NIH 0.11
D008173 Lung Diseases, Obstructive NIH 0.06
D029424 Pulmonary Disease, Chronic Obstructive NIH 0.06
D012140 Respiratory Tract Diseases NIH 0.05
D008171 Lung Diseases, NIH 0.04
D007249 Inflammation NIH 0.04

Correlated HPO Terms (5)


Name (Synonyms) Correlation
HP:0002099 Asthma HPO 1.00
HP:0012393 Allergy HPO 0.12
HP:0006536 Pulmonary obstruction HPO 0.06
Name (Synonyms) Correlation
HP:0006510 Chronic pulmonary obstruction HPO 0.06
HP:0002088 Abnormal lung morphology HPO 0.04

Clinical Trials

Navigate: Correlations   HPO

There are 15 clinical trials


1 Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations

Objective: To determine the extent to which high-dose (30mg) oral montelukast, added to standard treatment in children with moderate and severe acute exacerbations improves outcomes. Central Hypothesis: High-dose oral montelukast, added to standard treatment in children aged 5 to 17 years with moderate and severe acute asthma exacerbations, rapidly improves lung function, clinical severity, hospitalization rate and 72-hour symptom burden. Secondary Hypotheses: 1. There are greater effects of high-dose oral montelukast on lung function and on the secondary outcomes in the presence of respiratory viral detection or leukotriene-mediated inflammation; and 2. There is an interaction between viral detection and urinary leukotriene 4 level with treatment-response. Design: A two-arm, parallel randomized controlled trial of high-dose oral montelukast versus identical placebo, as add-on to standard treatment of systemic corticosteroid (SCS) and inhaled short-acting Beta-2-agonist (SABA), in children aged 5 to 17 years with moderate and severe acute asthma exacerbations. Intervention: High-dose oral montelukast added to standard treatment as one treatment-allocation arm, in comparison with standard treatment as the 2nd treatment-allocation arm. Primary and Important Secondary Endpoints: For the Primary Aim, the primary outcome measure to be compared between arms will be change of %-predicted airway resistance by impulse oscillometry (IOS) at 5Hz (%R5) at 2 hours after treatment initiation. Secondary outcomes will include improvement of %-predicted FEV1 (%FEV1), clinical severity measured using the validated Acute Asthma Intensity Research Score (AAIRS), hospitalization rate, and 72 hour symptom burden using the Pediatric Asthma Caregiver Diary (PACD). For the Secondary Aim, the investigators will determine (1) The effects of high-dose oral montelukast on lung function and on our secondary outcomes in the presence of nasal viruses and of greater leukotriene-mediated inflammation; and (2) The degree of interaction between viral detection and urinary leukotriene E4 (LTE4) level with treatment-response. Laboratory evaluations: The primary outcome (change of %R5) and select secondary outcomes (%FEV1, AAIRS, LTE4) will be measured before and again at 2 hours after treatment initiation. The other secondary outcomes will be measured at the time of hospitalization decision-making by the clinical team (hospitalization rate) or at 72-hours after treatment initiation (PACD).

NCT03277170
Conditions
  1. Asthma; Status
  2. Asthma in Children
  3. Asthma Acute
  4. Asthma Attack
  5. Acute Asthma Exacerbation
Interventions
  1. Drug: Montelukast Oral Granules
MeSH:Asthma
HPO:Asthma

Primary Outcomes

Description: Change of percent-predicted airway resistance at 5Hz (%R5) by impulse oscillometrypost montelukast or control administration

Measure: Change of percent-predicted airway resistance at 5Hz (%R5) by impulse oscillometry

Time: Before and 2-hours after treatment with montelukast or placebo

Secondary Outcomes

Description: Change of percent-predicted forced expiratory volume in 1-second (FEV1)

Measure: Change of percent-predicted forced expiratory volume in 1-second (FEV1)

Time: Before and 2-hours after treatment with montelukast or placebo

Description: Change of the Acute Asthma Intensity Research Score (AAIRS)

Measure: Change of the Acute Asthma Intensity Research Score (AAIRS)

Time: Before and 2-hours after treatment with montelukast or placebo

Description: Leukotriene E4 (LTE4)

Measure: Leukotriene E4 (LTE4)

Time: Before treatment with montelukast or placebo

Description: 72-hours symptom burden measured using the pediatric asthma caregiver diary (PACD)

Measure: 72-hours symptom burden measured using the pediatric asthma caregiver diary (PACD)

Time: Before and at 72-hours after treatment with montelukast or placebo

Description: Hospitalization rate

Measure: Hospitalization rate

Time: 8-hours after treatment with montelukast or placebo
2 One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study

Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study. Secondary Objectives: - To evaluate the long-term efficacy of dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study. - To evaluate dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study with regard to: - Systemic exposure. - Anti-drug antibodies (ADAs). - Biomarkers.

NCT03560466
Conditions
  1. Asthma
Interventions
  1. Drug: Dupilumab (SAR231893/REGN668)
  2. Drug: Asthma controller therapies (incl. prednisone/prednisolone)
  3. Drug: Asthma reliever therapies
MeSH:Asthma
HPO:Asthma

Primary Outcomes

Description: The number (n) and percentage (%) of patients experiencing any TEAE

Measure: Treatment-emergent adverse events (TEAEs)

Time: From Day 1 up to Week 64

Secondary Outcomes

Description: Annualized rate of severe asthma exacerbation events, during the treatment period

Measure: Severe asthma exacerbation events

Time: From Day 1 up to Week 52

Description: Change in percentage (%) predicted forced expiratory volume in 1 second (FEV1) - Clinically significant changes from baseline

Measure: Change in % predicted FEV1

Time: From Day 1 up to Week 64

Description: Change in absolute FEV1 - Clinically significant changes from baseline

Measure: Change in absolute FEV1

Time: From Day 1 up to Week 64

Description: Change in forced vital capacity (FVC)

Measure: Change in FVC

Time: From Day 1 up to Week 64

Description: Change in forced expiratory flow (FEF) 25-75%

Measure: Change in FEF

Time: From Day 1 up to Week 64

Description: Serum dupilumab concentrations - Changes from first dupilumab injection

Measure: Assessment of dupilumab concentration

Time: From Day 1 up to Week 64

Description: Titers of Anti-dupilumab antibodies

Measure: Assessment of immunogenicity

Time: From Day 1 up to Week 64

Description: Blood: Eosinophil count

Measure: Assessment of blood Eosinophil count

Time: From Day 1 up to Week 64

Description: Serum: total IgE

Measure: Assessment of total immunoglobulin E (IgE)

Time: From Day 1 up to Week 64
3 A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults With Inadequately Controlled Asthma on Inhaled Corticosteroids and at Least One Additional Asthma Controller (CASCADE)

A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.

NCT03688074
Conditions
  1. Asthma
  2. Bronchial Diseases
  3. Respiratory Tract Diseases
  4. Lung Diseases, Obstructive
  5. Lung Diseases
  6. Respiratory Hypersensitivity
  7. Hypersensitivity, Immediate
  8. Hypersensitivity
  9. Immune System Diseases
Interventions
  1. Biological: Tezepelumab
  2. Other: Placebo
MeSH:Asthma Lung Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Bronchial Diseases Respiratory Hypersensitivity Hypersensitivity Immune System Diseases Hypersensitivity, Immediate Inflammation
HPO:Abnormal lung morphology Allergy Asthma Pulmonary obstruction

Primary Outcomes

Description: The change from baseline in number of airway submucosal inflammatory cells/mm2 of bronchoscopic biopsies.

Measure: The change from baseline in number of airway submucosal inflammatory cells/mm2 of bronchoscopic biopsies.

Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.

Secondary Outcomes

Description: The change in reticular basement membrane (RBM) thickness from baseline, determined by microscopic evaluation of bronchoscopic biopsies

Measure: The change in reticular basement membrane (RBM) thickness from baseline, determined by microscopic evaluation of bronchoscopic biopsies

Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.

Description: The change in % airway epithelial integrity from baseline determined by microscopic evaluation of bronchoscopic biopsies

Measure: The change in % airway epithelial integrity from baseline determined by microscopic evaluation of bronchoscopic biopsies

Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.

Description: The change in number of airway submucosal inflammatory cells per mm2 from baseline, across the spectrum of T2 status, determined by microscopic evaluation of bronchoscopic biopsies

Measure: The change in number of airway submucosal inflammatory cells per mm2 from baseline, across the spectrum of T2 status, determined by microscopic evaluation of bronchoscopic biopsies

Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.
4 New Approaches for Empowering Studies of Asthma in Populations of African Descent

Background: Some groups of people have a high prevalence of asthma and allergic disease. Also, asthma and allergic disease are often found in several members of the same family. Researchers want to learn more about what factors might cause asthma, both genetic and environmental. Objective: To build a collection of information to try to find genes that cause conditions and disorders such as asthma and allergic disease. Eligibility: People ages 18 99 of self-identified African, African American, or African Caribbean descent who either have no history of asthma or wheeze or have a physician s diagnosis of asthma Design: Participants will be screened with an interview by phone or in person. Participants will fill out a questionnaire about their general health and exposure to allergens and smoke. Participants will have a physical exam. Participants will have blood tests. Participants will provide a skin cell sample. Up to two samples will be taken from the inside of the nose. A brush will be used to take the samples. Participants will have a breathing test. They will be asked to blow forcefully 3 or more times into a lung function machine. Participants may have their blood and skin samples sent to a lab. DNA will be extracted from the samples and tested. Participants blood and skin samples will be stored. Samples may be used in future research studies.

NCT03937804
Conditions
  1. Asthma
MeSH:Asthma
HPO:Asthma

Primary Outcomes

Description: Expand and integrate multiomic resources for asthma research in African Diaspora populations and identify novel genetic determinants for risk of asthma in CAAPA cohorts

Measure: Expand and integrate multiomic resources for asthma research in African Diaspora populations and identify novel genetic determinants for risk of asthma in CAAPA cohorts

Time: single assessment
5 Randomized, Open-label, Parallel Study to Investigate Safety and Efficacy of CARDIO Softgels Plus Best Standard-of-care vs. Best Standard-of-care Alone on a Former Smoker and/or Steroid-resistant Asthma Population With COVID-19 Infection

Corona virus disease 2019 (COVID-19) is caused by SARS-CoV-2, a plus-sense single-stranded RNA virus. After an incubation period, which typically lasts for 5-6 days, COVID-19 patients present with a mild illness that lasts for a few days. Common symptoms are reminiscent of the flu, and include fever, dry cough and dyspnea. A large percentage of patients resolve the infection whereas others progress onto adult respiratory distress syndrome (ARDS) which impedes gas exchange between the alveolar space and the bloodstream and creates the need for assisted respiration.The objectives of this randomized, open-label, parallel study is to investigate the safety and efficacy of CARDIO plus best standard-of-care in reducing the need for mechanical respiratory support, alleviating respiratory symptoms and reducing mortality in hospitalized former smoker and steroid-resistant asthma patients with COVID-19 infection.

NCT04465513
Conditions
  1. Asthma; Eosinophilic
  2. COVID
  3. Covid-19
Interventions
  1. Dietary Supplement: Best Standard of Care + CARDIO
  2. Dietary Supplement: Best Standard of Care
MeSH:Asthma Pulmonary Eosinophilia
HPO:Asthma

Primary Outcomes

Description: Oxygen saturation rates (Best Standard of Care treatment (BSC) plus CARDIO vs. BSC alone)

Measure: Oxygenation requirements during hospital stay (oxygen saturation rates)

Time: On day of discharge if earlier than 28 days from baseline, then 28 days from baseline

Description: Requirement for supplemental oxygen (Best Standard of Care treatment (BSC) plus CARDIO vs. BSC alone)

Measure: Oxygenation requirements during hospital stay (supplemental Oxygen)

Time: On day of discharge if earlier than 28 days from baseline, then 28 days from baseline

Description: Requirement for advanced ventilator support (Best Standard of Care treatment (BSC) plus CARDIO vs. BSC alone)

Measure: Oxygenation requirements during hospital stay (ventilator support)

Time: On day of discharge if earlier than 28 days from baseline, then 28 days from baseline

Secondary Outcomes

Description: Assessed by the National Early Warning Score (NEWS) which is a standardized tool that assesses disease severity and monitoring of patients in hospital. An aggregate score of respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness and temperature and the score is increased if supplemental oxygen is required. Each parameter is based on a scale of 0 - 3. 0=good, 3=poor

Measure: Clinical improvement

Time: Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: Assessed by the WHO Ordinal Scale for Clinical Improvement which examines changes in clinical status and/or survival specific to COVID-19. This 8-point scale measures illness severity over time. 0 = no infection and 8 = dead

Measure: Clinical status

Time: Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: Serial chest CT or X-ray findings for the CARDIO softgel + BSC group will be compared with those of the BSC group.

Measure: Serial chest CT or X-ray findings

Time: Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: This is defined as sustained normalization of fever, respiratory rate, oxygen saturation, and alleviation of cough for at least 72 hours

Measure: Time to clinical recovery

Time: Day 28 from baseline or day of discharge

Description: increase in SpO2/FiO2 of 50 mmHg or greater compared to the nadir SpO2/FiO2

Measure: Time to improvement in oxygenation for at least 48 hours

Time: Day 28 from baseline or day of discharge

Description: The number of days from hospital admission to hospital discharge

Measure: Hospitalization period

Time: Day 28 from baseline or day of discharge

Description: The total number of days on ventilator

Measure: Amount of time on Ventilator

Time: Day 28 from baseline or day of discharge

Description: number of days in intensive care unit (ICU)

Measure: Intensive Care stay

Time: Day 28 from baseline or day of discharge

Description: assessed by the COVID-19 QoL questionnaire which asks questions about incident of different parameters related to deteriorating. It is on a scale of 1-5. 1=completely disagree, 5 = completely agree

Measure: Quality of life (QoL)

Time: Day1, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: Death due to COVID-19 and other reasons

Measure: All-cause mortality

Time: Day 28 from baseline or day of discharge

Description: Body temperatures

Measure: Temperature measurements

Time: Day 28 from baseline or day of discharge

Description: measured using a pulse oximetry device, which is a non-invasive method to measure arterial oxygen saturation level.

Measure: Oxygen saturation measurements

Time: Day 28 from baseline or day of discharge

Description: assessed by the COVID-19 QoL questionnaire which asks questions about incident of different parameters related to deteriorating. It is on a scale of 1-5. 1=completely disagree, 5 = completely agree

Measure: COVID-19 QoL measurements

Time: Day 28 from baseline or day of discharge

Other Outcomes

Description: Incidence of pre-emergent and post-emergent adverse events (AEs) and serious adverse events (SAEs)

Measure: Adverse Events

Time: During 15 days of supplementation or until day of discharge and during home follow up

Description: systolic and diastolic

Measure: Blood pressure

Time: From baseline to 28 days thereafter

Description: Heart rate values for the CARDIO softgel + BSC group will be compared with those of the BSC group using

Measure: Heart rate

Time: Everyday From baseline to 28 days thereafter

Description: Frequency of clinically significant laboratory abnormalities.

Measure: Abnormality in laboratory tests

Time: Day 28 from baseline or day of discharge

Description: BMI values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

Measure: Body mass Index (BMI)

Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: CBC values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

Measure: Complete blood count (CBC)

Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: AST values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

Measure: Aspartate transaminase (AST)

Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: ALT values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

Measure: Alanine transaminase (ALT)

Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: ALP values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

Measure: Alkaline phosphatase (ALP)

Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: Bilirubin values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

Measure: Bilirubin

Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: Sodium ion values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

Measure: Sodium ion

Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: Potassium ion values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

Measure: Potassium ion

Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: Chloride ion values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

Measure: Chloride ion

Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: Creatinine values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

Measure: Creatinine

Time: Daily From baseline to 28 days thereafter

Description: eGFR values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

Measure: eGFR

Time: Daily From baseline to 28 days thereafter

Description: HbA1c values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

Measure: HbA1c

Time: Daily From baseline to 28 days thereafter

Description: eGFR values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

Measure: Glucose

Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

Description: CRP value only taken at baseline for every participant

Measure: C-Reactive protein (CRP)

Time: Baseline only
6 The Evaluation of Education With Cartoon's Effectiveness on Disease Management of the Children With Asthma

Objective: The aim of this study is to determine the effect of the education program (HPPCA - Health Promotion Program for Children with Asthma), which was developed by using cartoons and comic based on the health promotion model of Nola J Pender and brain-based learning theories, on disease control and life quality in children aged between 7 and 11, and diagnosed with asthma. Materials and Methods: The sample of the study consisted of 74 children between the ages of 7 and 11, who presented to a respiratory disease unit of a university hospital in Istanbul. Children were randomly assigned to the experimental (38 children) and control (36 children) groups using the Urn method. It was administered to both groups prior to the intervention. After the HPPCA education administered only to the experimental group, both groups were administered two post-tests as a follow-up in the 1st and 3rd months. Standardized sociodemographic question form, Childhood Asthma Control Test (C-ACT) and Paediatric Asthma Quality of Life Questionnaire (PAQLQ) were used for the follow-up. The data were evaluated using statistical parametric tests.

NCT04566835
Conditions
  1. Asthma in Children
Interventions
  1. Other: Standart Care given during normal examination
  2. Behavioral: Health Promotion Program with cartoon education for Children with Asthma
MeSH:Asthma
HPO:Asthma

Primary Outcomes

Description: The questionnaire has three sub-dimensions, which are symptoms, activity limitation and emotional function. The items related to the "Symptoms" sub-dimension are the items 4, 6, 8, 10, 12, 14, 16, 18, 20 and 23. The items 1, 2, 3, 19 and 22 are related to the "Activity Limitation" sub-dimension. Finally, the items 5, 7, 9, 11, 13, 15, 17 and 21 are related to the "Emotional Function" sub-dimension. While applying the questionnaire, the child should be alone. In the questionnaire, the value of each question is between 1 and 7 points, and the score weights of the questions are equal. The lowest score that could be obtained from the scale is 23, and the highest score is 161. The scores of all sub-categories are added together and the mean scores are calculated. Higher score indicates better quality of life

Measure: Paediatric Asthma Quality of Life Questionnaire - PAQLQ

Time: Pre Test

Description: The scale consists of two parts. The 4 questions asked in the first part are in VAS (visual analogue scale) type, and have 4 pictorial options. These questions are asked directly to the child and scored between 0 and 3. The remaining 3 questions are 6-Point Likert-type questions. They are reversely scored, from 5 to 0. This part has to be filled out by the parent. A score between 0 and 27 can be obtained on the scale. The cut-off point for the scale is 19. A score of 19 points or less obtained from the scale indicates that the asthma is not under control of the child.

Measure: Childhood Asthma Control Test

Time: Pre Test

Description: The scale consists of two parts. The 4 questions asked in the first part are in VAS (visual analogue scale) type, and have 4 pictorial options. These questions are asked directly to the child and scored between 0 and 3. The remaining 3 questions are 6-Point Likert-type questions. They are reversely scored, from 5 to 0. This part has to be filled out by the parent. A score between 0 and 27 can be obtained on the scale. The cut-off point for the scale is 19. A score of 19 points or less obtained from the scale indicates that the asthma is not under control of the child.

Measure: Childhood Asthma Control Test-Change from Pre Test on first month

Time: 1st month

Description: The questionnaire has three sub-dimensions, which are symptoms, activity limitation and emotional function. The items related to the "Symptoms" sub-dimension are the items 4, 6, 8, 10, 12, 14, 16, 18, 20 and 23. The items 1, 2, 3, 19 and 22 are related to the "Activity Limitation" sub-dimension. Finally, the items 5, 7, 9, 11, 13, 15, 17 and 21 are related to the "Emotional Function" sub-dimension. While applying the questionnaire, the child should be alone. In the questionnaire, the value of each question is between 1 and 7 points, and the score weights of the questions are equal. The lowest score that could be obtained from the scale is 23, and the highest score is 161. The scores of all sub-categories are added together and the mean scores are calculated. Higher score indicates better quality of life

Measure: Pediatric Asthma Quality of Life Questionnaire - Change from Pre Test on first month

Time: 1st month

Description: The scale consists of two parts. The 4 questions asked in the first part are in VAS (visual analogue scale) type, and have 4 pictorial options. These questions are asked directly to the child and scored between 0 and 3. The remaining 3 questions are 6-Point Likert-type questions. They are reversely scored, from 5 to 0. This part has to be filled out by the parent. A score between 0 and 27 can be obtained on the scale. The cut-off point for the scale is 19. A score of 19 points or less obtained from the scale indicates that the asthma is not under control of the child.

Measure: Childhood Asthma Control Test-Change from pretest, first month and fourth month

Time: 4th month

Description: The questionnaire has three sub-dimensions, which are symptoms, activity limitation and emotional function. The items related to the "Symptoms" sub-dimension are the items 4, 6, 8, 10, 12, 14, 16, 18, 20 and 23. The items 1, 2, 3, 19 and 22 are related to the "Activity Limitation" sub-dimension. Finally, the items 5, 7, 9, 11, 13, 15, 17 and 21 are related to the "Emotional Function" sub-dimension. While applying the questionnaire, the child should be alone. In the questionnaire, the value of each question is between 1 and 7 points, and the score weights of the questions are equal. The lowest score that could be obtained from the scale is 23, and the highest score is 161. The scores of all sub-categories are added together and the mean scores are calculated. Higher score indicates better quality of life

Measure: Pediatric Asthma Quality of Life Questionnaire - Change from pretest, first month and fourth month

Time: 4th month

Secondary Outcomes

Description: If child don't go to the school because of the asthma attack. The investigators evaluate it with a question. The investigators' question was; Have participants ever been absent from school due to asthma in the last four weeks' And the child answer it yes or no

Measure: Number of School absenteeism

Time: Pre Test

Description: unplanned outpatient clinic visits and emergency room visits. The investigators ask a question to parents; Have participants applied for an unplanned hospital admission due to asthma in the last four weeks?

Measure: Number of Hospital Visits

Time: Pre Test

Description: If child don't go to the school because of the asthma attack. And the investigators evaluate the change for school absenteeism with new question; Have participants ever been absent from school due to asthma in the last eight weeks. And this is a yes or no question.

Measure: Number of School absenteeism -Change from Pre Test on first month

Time: 1st month

Description: unplanned outpatient clinic visits and emergency room visits.Have participants applied for an unplanned hospital admission due to asthma in the eight weeks? They should answer it yes or no.

Measure: Number of Hospital Visits -Change from Pre Test on first month

Time: 1st month

Description: If child don't go to the school because of the asthma attack. The investigators ask the question again; Have participants been absent from school due to asthma in the last four months? And the child should answer it yes or no.

Measure: Number of School absenteeism -Change from pretest to first month and fourth month

Time: 4th month

Description: unplanned outpatient clinic visits and emergency room visits. The investigators ask them a question; Have participants applied for an unplanned hospital admission due to asthma in the last four months? The investigators expect them to answer it yes or no.

Measure: Number of Hospital Visits-Change from pretest, first month and fourth month

Time: 4th month
7 A Phase II, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MEDI3506 in Adult Participants With Uncontrolled Moderate-to-severe Asthma

Study D9181C00001 is a Phase II, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of MEDI3506 in adult participants with uncontrolled moderate to severe asthma on standard of care (SOC). Up to approximately 80 sites globally will participate in this study. Approximately 228 participants will be randomized to 3 treatment groups in a 1:1:1 ratio to receive MEDI3506 dose 1, MEDI3506 dose 2, or placebo.

NCT04570657
Conditions
  1. Asthma
Interventions
  1. Biological: MEDI3506
  2. Drug: Placebo
MeSH:Asthma
HPO:Asthma

Primary Outcomes

Description: To assess the effect of MEDI3506 compared with placebo on lung function, in adult participants with uncontrolled moderate-to-severe asthma.

Measure: Change from baseline to Week 16 in pre-BD FEV1 (L)

Time: From Baseline to Week 16

Secondary Outcomes

Description: To assess the PK of MEDI3506 in adult participants with uncontrolled moderate-to-severe asthma

Measure: Serum MEDI3506 concentration-time profiles from Study Day 1 until Study Day 169

Time: from Study Day 1 to Study Day 169 for a total of 24 weeks

Description: To assess the immunogenicity of MEDI3506 in adult participants with uncontrolled moderate-to-severe asthma.

Measure: ADA during the intervention and follow-up periods

Time: from Study Day 1 to Study Day 169 for a total of 24 weeks

Description: To assess the effect of MEDI3506 compared with placebo on asthma control in adult participants with uncontrolled moderate-to-severe asthma.

Measure: Change from baseline to Week 16 in ACQ-6 score.

Time: Baseline to Week 16

Description: To assess the effect of MEDI3506 compared with placebo on asthma control in adult participants with uncontrolled moderate-to-severe

Measure: Proportion of participants with a decrease in ACQ-6 score of ≥ 0.5 from baseline to Week 16

Time: Baseline to Week 16

Description: To assess the effect of MEDI3506 compared with placebo on asthma control in adult participants with uncontrolled moderate-to-severe

Measure: Proportion of participants achieving ACQ-6 well controlled status (defined as ACQ-6 score ≤ 0.75 at Week 16)

Time: Week 16

Description: To assess the effect of MEDI3506 compared with placebo on health status in adult participants with uncontrolled moderate-to-severe asthma.

Measure: Change from baseline in SGRQ at Week 16

Time: Baseline to Week 16

Description: To assess the effect of MEDI3506 compared with placebo on health status in adult participants with uncontrolled moderate-to-severe asthma.

Measure: Proportion of participants with a decrease in SGRQ total score of ≥ 4 points from baseline to Week 16.

Time: Baseline to Week 16

Description: To further assess the effect of MEDI3506 compared with placebo on lung function, in adult participants with uncontrolled moderate-to-severe asthma

Measure: Change from baseline to Weeks 8 and 16 in post-BD FEV1 (L)

Time: From baseline to Weeks 8 and 16

Description: To assess the effect of MEDI3506 compared with placebo on CompEx in adult participants with uncontrolled moderate-to-severe asthma

Measure: Time to first CompEx event based on the period from baseline to Week 16

Time: Baseline to Week 16

Description: To assess the effect of MEDI3506 compared with placebo on CompEx in adult participants with uncontrolled moderate-to-severe asthma.

Measure: Annualised CompEx event rate

Time: Baseline to Week 16

Description: To assess the effect of MEDI3506 compared with placebo on concentration of FeNO in adult participants with uncontrolled moderate-to-severe asthma

Measure: Percent change from baseline to Week 16 in concentration of FeNO in exhaled breath

Time: From baseline to Week 16
8 A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma

This is a Phase 1b, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetic profiles of voriconazole inhalation powder in adult subjects with well-controlled asthma. This study will involve 2 cohorts.

NCT04576325
Conditions
  1. Asthma
Interventions
  1. Drug: Voriconazole Inhalation Powder
  2. Drug: Placebo
MeSH:Asthma
HPO:Asthma

Primary Outcomes

Description: Frequency of AEs, SAEs, and discontinuations due to AEs

Measure: Number of participants who experience Adverse Events (AEs), Serious Adverse Events (SAEs) and withdrawals due to AEs

Time: Through study completion, an average of 14 days

Description: Number of participants with potentially clinically significant vital sign values

Measure: Number of participants who experience vital sign abnormalities

Time: Baseline through study completion, an average of 14 days

Description: Number of participants with potentially clinically significant pulse oximetry values

Measure: Number of participants who experience pulse oximetry abnormalities

Time: Baseline through study completion, an average of 14 days

Description: Spirometry used to measure FEV1 lung function

Measure: Mean change from baseline in forced expiratory volume (FEV1)

Time: Baseline through study completion, an average of 14 days

Description: Spirometry used to measure FVC lung function

Measure: Mean change from baseline in forced vital capacity (FVC)

Time: Baseline through study completion, an average of 14 days

Description: Spirometry used to measure FVC and FEF25-75% lung function

Measure: Mean change from baseline in forced expiratory flow over the middle 1/2 of the FVC (FEF25-75%)

Time: Baseline through study completion, an average of 14 days

Description: Spirometry used to measure FEV1 and FVC lung function

Measure: Mean change from baseline in FEV1/FVC ratio

Time: Baseline through study completion, an average of 14 days

Description: Number of participants with potentially clinically significant ECG values

Measure: Mean change from baseline in QTcF changes via ECG

Time: Baseline through study completion, an average of 14 days

Description: Number of participants with potentially clinically significant physical examination findings

Measure: Number of participants who experience physical examination abnormalities

Time: Baseline through study completion, an average of 14 days

Description: Number of participants with potentially clinically significant laboratory test results

Measure: Number of participants who experience laboratory test abnormalities

Time: Baseline through study completion, an average of 14 days

Secondary Outcomes

Description: Blood samples will be collected for plasma analysis

Measure: PK of VIP in plasma: Area under the plasma-concentration time curve (AUC)

Time: Predose Day 1 and through 12 hours post last dose (day 4)

Description: Blood samples will be collected for analysis

Measure: PK of VIP in plasma: Area under the plasma-concentration time curve over the first 12 hours after dosing (AUC0-12)

Time: Predose Day 1 and through 12 hours post last dose (day 4)

Description: Blood samples will be collected for analysis

Measure: PK of VIP in plasma: Area under the concentration time curve, from time 0 to the last observed non-zero concentration (AUC0-tlast)

Time: Predose Day 1 and through 12 hours post last dose (day 4)

Description: Blood samples will be collected for analysis

Measure: PK of VIP in plasma: Area under the concentration time curve from time 0 extrapolated to infinity (AUC∞)

Time: Predose Day 1 and through 12 hours post last dose (day 4)

Description: Blood samples will be collected for analysis

Measure: PK of VIP in plasma: Maximum observed concentration (Cmax)

Time: Predose Day 1 and through 12 hours post last dose (day 4)

Description: Blood samples will be collected for analysis

Measure: PK of VIP in plasma: Time to maximal observed concentration (tmax)

Time: Predose Day 1 and through 12 hours post last dose (day 4)

Description: Blood samples will be collected for analysis

Measure: PK of VIP in plasma: Termination elimination half-life (t½)

Time: Predose Day 1 and through 12 hours post last dose (day 4)

Description: Blood samples will be collected for analysis

Measure: PK of VIP in plasma: Apparent total body clearance (CL/F)

Time: Predose Day 1 and through 12 hours post last dose (day 4)

Description: Blood samples will be collected for analysis

Measure: PK of VIP in plasma: Apparent volume of distribution during the terminal elimination phase (Vz/F)

Time: Predose Day 1 and through 12 hours post last dose (day 4)
9 A Randomised Double-blind, Placebo Controlled, Single Ascending and Repeat Dose, First Time in Human Study in Healthy Participants and Stable Asthmatics to Assess Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder

This is a first time in human (FTIH) study designed to evaluate the safety, tolerability and pharmacokinetic (PK) profile of single and repeat doses of GSK3923868 inhalation powder in both healthy participants and asthmatics. This is a 3-part, randomized, double blind, placebo controlled study of GSK3923868, administered as an inhalation powder blend (GSK3923868 capsules for inhalation) via Mono-dose inhaler in healthy participants (Parts A and B) and in participants with asthma (Part C). The duration of study participation for each part A, B and C will be 11, 9 and 8 weeks, respectively.

NCT04585009
Conditions
  1. Pulmonary Disease, Chronic Obstructive
Interventions
  1. Drug: GSK3923868
  2. Drug: Matching placebo
  3. Device: Monodose RS01
MeSH:Respiratory Aspiration Asthma Pulmonary Disease, Chronic Obstructive
HPO:Asthma Chronic pulmonary obstruction

Primary Outcomes

Description: AEs and SAEs will be collected.

Measure: Part A: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

Description: AEs and SAEs will be collected.

Measure: Part B: Number of participants with AEs and SAEs

Time: From start of the treatment (Day 0) to Day 18

Description: AEs and SAEs will be collected.

Measure: Part C: Number of participants with AEs and SAEs

Time: From start of the treatment (Day 0) to Day 8

Description: Blood samples will be collected for the assessment of hematology laboratory (lab) parameters.

Measure: Part A: Number of participants with clinically significant changes in hematology lab parameters

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

Description: Blood samples will be collected for the assessment of clinical chemistry lab parameters.

Measure: Part A: Number of participants with clinically significant changes in clinical chemistry lab parameters

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

Description: Urine samples will be collected for the assessment of urinalysis lab parameters.

Measure: Part A: Number of participants with clinically significant changes in urinalysis lab parameters

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

Description: Blood samples will be collected for the assessment of hematology lab parameters.

Measure: Part B: Number of participants with clinically significant changes in hematology lab parameters

Time: From start of the treatment (Day 0) to Day 18

Description: Blood samples will be collected for the assessment of clinical chemistry lab parameters.

Measure: Part B: Number of participants with clinically significant changes in clinical chemistry lab parameters

Time: From start of the treatment (Day 0) to Day 18

Description: Urine samples will be collected for the assessment of urinalysis lab parameters.

Measure: Part B: Number of participants with clinically significant changes in urinalysis lab parameters

Time: From start of the treatment (Day 0) to Day 18

Description: Blood samples will be collected for the assessment of hematology lab parameters.

Measure: Part C: Number of participants with clinically significant changes in hematology lab parameters

Time: From start of the treatment (Day 0) to Day 8

Description: Blood samples will be collected for the assessment of clinical chemistry lab parameters.

Measure: Part C: Number of participants with clinically significant changes in clinical chemistry lab parameters

Time: From start of the treatment (Day 0) to Day 8

Description: Urine samples will be collected for the assessment of urinalysis lab parameters.

Measure: Part C: Number of participants with clinically significant changes in urinalysis lab parameters

Time: From start of the treatment (Day 0) to Day 8

Description: Vital signs will be measured in a semi-supine position after atleast 10 minutes rest.

Measure: Part A: Number of participants with clinically significant vital signs

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

Description: Vital signs will be measured in a semi-supine position after atleast 10 minutes rest.

Measure: Part B: Number of participants with clinically significant vital signs

Time: From start of the treatment (Day 0) to Day 18

Description: Vital signs will be measured in a semi-supine position after atleast 10 minutes rest.

Measure: Part C: Number of participants with clinically significant vital signs

Time: From start of the treatment (Day 0) to Day 8

Description: Twelve-lead electrocardiogram will be performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and corrected QT intervals (QTc). The QT interval will be corrected for heart rate by Fredericia's formula (QTcF).

Measure: Part A: Number of participants with clinically significant abnormalities in 12-Lead electrocardiogram (ECG) findings

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

Description: Twelve-lead electrocardiogram will be performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QTc.

Measure: Part B: Number of participants with clinically significant abnormalities in 12-Lead ECG findings

Time: From start of the treatment (Day 0) to Day 18

Description: Twelve-lead electrocardiogram will be performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QTc.

Measure: Part C: Number of participants with clinically significant abnormalities in 12-Lead ECG findings

Time: From start of the treatment (Day 0) to Day 8

Description: Spirometry measurements including forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) will be assessed

Measure: Part A: Number of participants with clinically significant abnormalities in spirometry measurements

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

Description: Spirometry measurements including FEV1 and FVC will be assessed.

Measure: Part B: Number of participants with clinically significant abnormalities in spirometry measurements

Time: From start of the treatment (Day 0) to Day 18

Description: Spirometry measurements including FEV1 and FVC will be assessed.

Measure: Part C: Number of participants with clinically significant abnormalities in spirometry measurements

Time: From start of the treatment (Day 0) to Day 8

Secondary Outcomes

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part A, Cohort 1 and 2: Area under the plasma GSK3923868 concentration versus time curve from time zero to last quantifiable concentration (AUC[0-t])

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

Description: Blood samples will be collected for the concentration of GSK3923868.

Measure: Part A, Cohort 1 and 2: Area under the plasma GSK3923868 concentration versus time curve from time zero to infinity (AUC[0-inf])

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part A, Cohort 1 and 2: Maximum observed GSK3923868 plasma concentration (Cmax)

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part A, Cohort 1 and 2: Time to maximum observed plasma drug concentration (Tmax)

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part B, Cohort 3 and 4: AUC from time 0 (predose) to time tau (AUC [0-tau]) (tau=24hours for once a day dosing regimen) of GSK3923868 on Day 1 and Day 14

Time: Day 1 and 14: Up to 24 hours post dose

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part B, Cohort 3 and 4: Cmax of GSK3923868 on Day 1 and Day 14

Time: Day 1 and Day 14

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part B, Cohort 3 and 4: Tmax of GSK3923868 on Day 1 and Day 14

Time: Day 1 and Day 14

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part C: AUC (0-tau) (tau=24hours for once a day dosing regimen)of GSK3923868 on Day 1 and Day 7

Time: Day 1 and 7: Up to 24 hours post dose

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part C: Cmax of GSK3923868 on Day 1 and Day 7

Time: Day 1 and Day 7

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part C: Tmax of GSK3923868 on Day 1 and Day 7

Time: Day 1 and Day 7
10 An Open-label, Two-period, Single-sequence, Crossover Study to Compare the Systemic Exposure of a Single Inhaled Dose of Mometasone Furoate (MF) When Administered Alone Via the MF Twisthaler® (TH) to a Single Inhaled Dose of QMF149 Indacaterol Acetate/MF Fixed Dose Combination When Administered Via the Concept 1 (Breezhaler®) Device in ≥ 6 to <12 Year Old Asthma Patients

This is an open-label, two-period, single-sequence crossover study including 2 single dose treatments of mometasone furoate 100 μg administered via Twisthaler® and of 75/40 µg indacaterol acetate/mometasone furoate fixed dose combination 75/40 µg (QMF149) administered via Concept 1 device with a washout period between the two treatments. The study will include a screening period of up to 14 days, two single-dose treatments separated by a 4-7 day washout period (4 days is the minimum washout) and a 30-day investigational drug-free follow-up period.

NCT04589663
Conditions
  1. Asthma
Interventions
  1. Drug: Mometasone furoate
  2. Drug: QMF149
MeSH:Asthma
HPO:Asthma

Primary Outcomes

Description: Mometasone furoate plasma concentrations will be determined by a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) method. Cmax of mometasone furoate will be determined with Phoenix WinNonlin (Version 6.4 or higher).

Measure: Maximum observed mometasone furoate plasma concentration (Cmax)

Time: pre-dose, 0.5, 1, 2, 3 and 6 hours post-dose on Day 1 and Day 6

Description: AUC0-6h of mometasone furoate will be determined using non-compartment methods with Phoenix WinNonlin (Version 6.4 or higher). The linear trapezoidal rule will be used for AUC0-6h calculation.

Measure: Area under the plasma concentration-time curve from time zero to the last sampling time point 6h (AUC0-6h) of mometasone furoate

Time: pre-dose, 0.5, 1, 2, 3 and 6 hours post-dose on Day 1 and Day 6

Secondary Outcomes

Description: Systemic exposure to indacaterol in plasma following sparse pharmacokinetic (PK) sampling on Day 6 after inhalation of QMF149.

Measure: Systemic exposure to indacaterol in plasma

Time: pre-dose, 0.25 and 1 hour post-dose on Day 6
11 Evaluatıng The Effects Of Web Desıgn In Educatıng Asthma Patıents On Drug Complıance And Qualıty Of Lıfe

The study is an experimental study with a methodological and pre-test-post-test control group in order to determine the effect of web-designed education developed for asthmatic patients on drug compliance and quality of life.

NCT04607681
Conditions
  1. Asthma
Interventions
  1. Behavioral: WEB BASED EDUCATION
MeSH:Asthma
HPO:Asthma

Primary Outcomes

Description: Medication Compliance Reporting Scale Participants are asked to indicate the frequency of the 5 statements in each of them. The scale is evaluated with a 5-point Likert type such that 5 = never, 4 = rarely, 3 = sometimes, 2 = often and 1 = always. The total test score is obtained by summing the scores obtained from the items. The scores obtained from the scale range from 5 to 25. An increase in the obtained scores indicates compatibility, and a decrease in scores indicates incompatibility.

Measure: change from baseline in Medication Compliance Reporting Scaleat week 6

Time: baseline and 6 weeks

Description: COPD and Asthma Fatigue Scale (DAS) The scale consists of 12 items, and a Likert type rating (1 = never, 2 = rarely, 3 = sometimes, 4 = often, 5 = very often) is used for its answers. In calculating the scale score, the first 10 questions correspond to never = 1 point, rarely = 2 points, sometimes = 3 points, often = 4 points, very often = 5 points, and in the 11th and 12th questions never = 5 points, rarely = 4 points. , sometimes = 3 points, often = 2 points, very often = 1. The total raw score is determined by adding the scores of each item and the raw scores are converted into a total scale score between 0-100. The higher the score obtained from the scale indicates that the fatigue level of the person is high.

Measure: change from baseline in COPD and Asthma Fatigue Scale (DAS) at week 6

Time: baseline and 6 weeks

Description: Asthma Control Test (AKT); This scale consists of five Likert type and consists of five questions. The maximum score of this test is 25 and the minimum score is 5, while 25 points are "full control", 20-24 points "good control" and a score of less than 19 is considered "uncontrolled"

Measure: change from baseline in Asthma Control Test (AKT) week 6

Time: baseline and 6 weeks

Description: Opinion Form Regarding the Web Based Asthma Education Program This form contains 20 questions prepared to determine the views of asthma patients on the web-based asthma education program.

Measure: evaluating the web-based asthma education program

Time: baseline and 6 weeks
12 Efficacy of Mepolizumab in Patients With Late-onset Severe Eosinophilic Asthma and Fixed Obstruction

Interleukin (IL)-5 is the main cytokine responsible for the activation of eosinophils, hence therapeutic strategies have been investigated and developed for clinical use. Biologics targeting IL-5 and its receptor (first mepolizumab and subsequently, reslizumab and benralizumab), have been recently approved and used as add-on therapy for severe eosinophilic asthma resulting in a reduction in the circulating eosinophil count, improvement in lung function and exacerbation reduction in patients with severe asthma. Response to biologic therapies in severe asthma is variable, with patients being either non-responders, responders or super-responders. There is currently no explanation for this broad variation in response. It is important to examine whether these patients have distinct characteristics that could help the treating physician in making the correct diagnosis in clinical practice. Aim of this clinical study is to evaluate the efficacy of mepolizumab, a humanized IL-5 antagonist monoclonal antibody in patients with late-onset severe eosinophilic asthma with fixed obstruction and to identify the characteristics of non-responders and super-responders under mepolizumab treatment. This study is considered as non-interventional and every procedure included is happening in a clinical routine for the diagnosis and phenotyping of the asthmatic patients. Hypothesis includes the efficacy of mepolizumab treatment in late-onset severe eosinophilic asthmatic patients with fixed obstruction and relation to clinical and inflammatory biomarkers. Patients will be collected from the outpatient clinics of bronchial asthma from each site included (8 in number) which cover the whole population of Greece. Overall, this is a prospective multicenter study including eight Pulmonary Clinics. Five Pulmonary University Clinics, two of National Health System and one Army General Hospital in Thessaloniki. The study will include a screening period of up to 2 weeks to assess eligibility and obtain written informed consent, a mepolizumab treatment period of 52 weeks, once every 4 weeks, including follow up visits every 3 months during treatment. The study population will consist of 45 patients with late-onset severe eosinophilic asthma and fixed obstruction receiving mepolizumab, aged 20 and above.

NCT04612556
Conditions
  1. Asthma; Eosinophilic
  2. Severe Asthma
  3. Late-Onset Asthma
Interventions
  1. Drug: Mepolizumab 100 MG [Nucala]
MeSH:Asthma Pulmonary Eosinophilia
HPO:Asthma

Primary Outcomes

Description: Mesurement of the change in exacerbation rate in each late-onset severe eosinophilic asthmatic patient with fixed obstruction under mepolizumab treatment for 52 weeks of treatment.

Measure: Change in exacerbation rate

Time: through study completion, 52 weeks

Description: The identification of clinical characteristics of non-responders and super-responders. FEV1 change from baseline, before treatment initiation, compared to measurements every 3 months until 1 year of treatment. FEV1 is the maximal amount of air you can forcefully exhale in one second measured by spirometry.

Measure: Identification of clinical characteristics of response, change in Forced Expiratory Volume (FEV1)

Time: through study completion, 52 weeks

Description: The identification of clinical characteristics of non-responders and super-responders. Change from baseline, before treatment initiation, compared to measurements every 3 months until 1 year of treatment.

Measure: Identification of clinical characteristics of response, change in blood eosinophil levels.

Time: through study completion, 52 weeks

Description: The identification of clinical characteristics of non-responders and super-responders. Change from baseline, before treatment initiation, compared to measurements every 3 months until 1 year of treatment.

Measure: Identification of clinical characteristics of response, change in FENO levels.

Time: through study completion, 52 weeks

Description: Identification of any improvement in patients' quality of life during mepolizumab treatment in late-onset severe eosinophilic asthmatic patients with fixed obstruction, from baseline, before treatment initiation, compared to every 3 months until 1 year of treatment. Questionnaire included: the Asthma Control Questionnaire (ACQ-5) to assess current asthma control. Scores range between 0 (totally controlled) and 6 (severely uncontrolled).

Measure: Identification of clinical characteristics of response, change in Asthma Control Questionnaire

Time: through study completion, 52 weeks

Description: Identification of any improvement in patients' quality of life during mepolizumab treatment in late-onset severe eosinophilic asthmatic patients with fixed obstruction, from baseline, before treatment initiation, compared to every 3 months until 1 year of treatment. Questionnaire included: Asthma Control Test (ACT) to assess current asthma control. The scores range from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. An ACT score >19 indicates well-controlled asthma.

Measure: Identification of clinical characteristics of response, change in Asthma Control Test

Time: through study completion, 52 weeks

Description: Identification of any improvement in patients' quality of life during mepolizumab treatment in late-onset severe eosinophilic asthmatic patients with fixed obstruction, from baseline, before treatment initiation, compared to every 3 months until 1 year of treatment. Questionnaire included: the Asthma Quality of Life Questionnaire (AQLQ+12) to assess quality of life and psychological morbidity. Scores range 1-7, with higher scores indicating better quality of life.

Measure: Identification of clinical characteristics of response, change in Asthma Quality of Life Questionnaire

Time: through study completion, 52 weeks

Description: Identification of any improvement in patients' quality of life during mepolizumab treatment in late-onset severe eosinophilic asthmatic patients with fixed obstruction, from baseline, before treatment initiation, compared to every 3 months until 1 year of treatment. Questionnaire included: Athens Insomnia Scale (AIS) to assess sleeping quality. Total score range form 0 to 24 with higher scores indicating worst sleeping quality. AIS includes 8 questions with scores range from 0 (meaning that the item in question has not been a problem) to 3 (indicating more acute sleep difficulties).

Measure: Identification of clinical characteristics of response, change in Athens Insomnia Scale

Time: through study completion, 52 weeks

Description: Identification of any improvement in patients' quality of life during mepolizumab treatment in late-onset severe eosinophilic asthmatic patients with fixed obstruction, from baseline, before treatment initiation, compared to every 3 months until 1 year of treatment. Questionnaire included: Epworth Sleepiness Scale (ESS) to assess sleeping quality. The total score can range from 0 to 24. Higher scores indicate increased sleepiness.

Measure: Identification of clinical characteristics of response, change in Epworth Sleepiness Scale

Time: through study completion, 52 weeks

Description: Identification of any improvement in patients' quality of life during mepolizumab treatment in late-onset severe eosinophilic asthmatic patients with fixed obstruction, from baseline, before treatment initiation, compared to every 3 months until 1 year of treatment. Questionnaire included: St. George's Respiratory Questionnaire (SGRQ) to assess sleeping quality. Scores range from 0 to 100, with higher scores indicating more limitations.

Measure: Identification of clinical characteristics of response, change in St. George's Respiratory Questionnaire

Time: through study completion, 52 weeks

Description: Identification of any improvement in patients' quality of life during mepolizumab treatment in late-onset severe eosinophilic asthmatic patients with fixed obstruction, from baseline, before treatment initiation, compared to every 3 months until 1 year of treatment. Questionnaire included: WHO (Five) Well-Being Index (WHO-5) to assess sleeping quality. The total raw score ranges from 0 to 25, is multiplied by 4 to give the final score, with 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being.

Measure: Identification of clinical characteristics of response, change in WHO (Five) Well-Being Index

Time: through study completion, 52 weeks

Description: Identification of any improvement in patients' quality of life during mepolizumab treatment in late-onset severe eosinophilic asthmatic patients with fixed obstruction, from baseline, before treatment initiation, compared to every 3 months until 1 year of treatment. Questionnaire included: Fatigue Severity Scale (FSS) to assess sleeping quality. FSS includes a 9-item questionnaire with questions scored on a 7 point scale with 1 meaning strongly disagree and 7 meaning strongly agree. Scores range from 9 to 63. Higher the score indicates greater fatigue severity.

Measure: Identification of clinical characteristics of response, change in Fatigue Severity Scale

Time: through study completion, 52 weeks

Secondary Outcomes

Description: The identification of clinical characteristics of non-responders and super-responders. Any improvement in smooth muscle cell mass will be measured as change from baseline compared to measurement after 1 year of treatment. Increased smooth muscle cell mass indicates airway remodeling and loss of pulmonary function. Smooth muscle cell mass will be determined through the epithelial integrity, reticular basement membrane length and vascularity area.

Measure: Change in smooth muscle cell mass

Time: through study completion, 52 weeks

Description: To identify any possible biomarkers of response of non-responders versus super-responders in different biological fluids as peripheral blood, bronchial washing, sputum, sputum supernatant. The identification of clinical characteristics of non-responders and super-responders. Change from baseline compared to measurements after 6 months and after 1 year of mepolizumab treatment.

Measure: Change of T-lympocytes percentages

Time: through study completion, 52 weeks

Description: To identify any possible biomarkers of response of non-responders versus super-responders in different biological fluids as peripheral blood, bronchial washing, sputum, sputum supernatant. The identification of clinical characteristics of non-responders and super-responders. Change from baseline compared to measurements after 6 months and after 1 year of mepolizumab treatment.

Measure: Change of cytokine and protein levels

Time: through study completion, 52 weeks
13 Health-Related Quality of Life of Patients With Asthma and Its Associated Factors During the Pandemic of COVID-19

Nowadays, the COVID-19 epidemic causes stress not only to healthy people but also to people with unhealthy conditions. Excess psychological stress (either in quality, quantity, frequency, and/or duration) could push susceptible individuals to ultimately develop clinical asthma. Depression was significantly associated with asthma interference with daily activities, breathlessness, night symptoms, use of bronchodilators, and poor compliance with medical treatment. Covid-19 pandemic induced the countries around the world to require from its citizens not to ask for health care support rather than in emergency situations and through utilizing telemedicine. This action aims to control spreading the infection with viruses as well as to reduce the workload on the healthcare providers. Although asthma is not listed as one of the chronic conditions that might complicate coronavirus infections, asthma people might have a high-stress level that might induce their asthma attack which consequentially reflects on their quality of life. People with asthma have a unique experience rather than people with other health conditions during COVID-19. Patients with asthma experience a lot of stressors that might induce asthma and impaired their HRQOL such as overuse of antiseptic substances, stay home with a sedentary lifestyle, the sudden shift to telemedicine, and electronic work from home. Also, as a result of the similarity of asthma symptoms with coronavirus symptoms, the patient might have a continuous sense of uncertainty that s/he is infected with the COVID-19 virus, and this suspicion can increase the psychological overburden on these patients. Therefore, all these stressors should be evaluated to recognize their health needs and the kind of social and health support that should be provided to them during the pandemic time. Also, Identifying the predictors of HRQOL among patients with asthma during the pandemic of COVID-19 is urgently required.

NCT04613245
Conditions
  1. Asthma Chronic
  2. Bronchial Asthma
MeSH:Asthma
HPO:Asthma

Primary Outcomes

Description: ACQ has a multidimensional construct assessing symptoms (5 items--self-administered) and rescue in bronchodilator use (1 item-self-administered), and FEV1% (1 item) completed by clinic staff, but it will not be applied in the current study as it will be difficult to be self-reported by the participants. 7-point scale (0=no impairment, 6= maximum impairment for symptoms. Scores range between 0 (totally controlled) and 6 (severely uncontrolled).

Measure: Asthma Control Questionnaire (ACQ)

Time: One week

Secondary Outcomes

Description: The MiniAQLQ will be utilized to investigate the HRQoL of the participants. The Mini AQLQ-S has 15 questions that gives an overall summary index and four domains: activity limitation, symptoms, emotional function, and environmental stimuli. The questions all refer to the "last two weeks" and use seven Likert-type response options e.g., seven response options ranging from "all of the time" to "none of the time".

Measure: Mini Asthma Quality of Life Questionnaire

Time: two weeks

Description: Perceived Stress Scale is a self-reported measure of the degree to which situations in an individual's life are perceived as stressful. PSS has 14 items can assess the degree to which individuals found their life unpredictable, uncontrollable, and overloaded.

Measure: Perceived Stress Scale

Time: month
14 Comparing Patient-Centered Outcomes for Adults and Children With Asthma in High-Deductible Health Plans With and Without Preventive Drug Lists: COVID Enhancement

In addition to its impact on health, the COVID-19 pandemic has led to increased unemployment and loss of employer-sponsored insurance coverage. Obtaining coverage can be challenging and eligibility for public programs and subsidies can be limited, and those who do not qualify can face steep premiums, high-deductibles, and high out-of-pocket costs. Patients with asthma are at risk for adverse health outcomes during the COVID-19 pandemic, and disruptions to employment and insurance coverage during the pandemic threaten to negatively affect asthma care and outcomes. Our PCORI-funded parent project, Asthma in Families Facing Out-of-pocket Requirements with Deductibles (AFFORD), found that patients with asthma may be particularly vulnerable to insurance-related cost barriers and challenges navigating health insurance. Together with the Asthma and Allergy Foundation of America (AAFA), the investigators developed an asthma chat bot to help patients with asthma navigate insurance benefits and optimize health care decisions. The chat bot is an artificial intelligence-enabled interactive online tool that can answer clinical and insurance-related questions and provide information on coverage and how to find lower-cost alternatives for asthma care. In this supplement to the AFFORD project, the investigators propose a new study to understand and address the insurance and health care cost challenges faced by patients with asthma who lose employer-sponsored coverage due to COVID-19. Our Aims are: 1) to conduct a pilot randomized controlled trial to evaluate the effectiveness and feasibility and acceptability of an insurance navigation intervention, including the chat bot, to help patients with asthma regain coverage after the loss of job-related insurance during the COVID-19 pandemic; and 2) to qualitatively explore the experiences of Aim 1 participants to understand barriers and facilitators to accessing coverage and asthma care more broadly during the COVID-19 pandemic The study hypothesis is that participants receiving the intervention will be more likely to have coverage after four months and less likely to report non-adherence to asthma medications, delayed/forgone asthma care, and financial burden than those receiving usual care. Findings will provide evidence about the effectiveness of strategies to obtain coverage and maintain access to affordable asthma care and can inform ongoing and future decision making in response to the COVID-19 pandemic and other public health and economic threats.

NCT04613739
Conditions
  1. Asthma
Interventions
  1. Behavioral: insurance navigation
MeSH:Asthma
HPO:Asthma

Primary Outcomes

Description: Change in coverage status (has any insurance coverage or not)

Measure: Insurance coverage

Time: From baseline to follow-up (four months)

Secondary Outcomes

Description: Change in report of using less asthma medication than prescribed because of cost

Measure: Medication adherence

Time: From baseline to follow-up (four months)

Description: Change in report of: 1) problems paying medical bills for asthma care, or 2) having to borrow money because of the amount required to pay for asthma care

Measure: Financial burden

Time: From baseline to follow-up (four months)

Description: Change in report of: 1) using less asthma medication than prescribed because of cost,or 2) delaying or avoiding going to the doctor for asthma because of cost

Measure: Delayed/forgone care due to cost

Time: From baseline to follow-up (four months)
15 A Two-part Phase IIa Randomised, Double-blind, Placebo-controlled, Dose-ranging, Multi-centre Study to Assess Efficacy and Safety of Three Inhaled Dose Levels of AZD1402 Administered as a Dry Powder for Four Weeks in Adults With Asthma on Medium Dose Inhaled Corticosteroids

This is a randomised, placebo-controlled, double-blinded, multi-centre, 2-part study to assess the efficacy and safety of inhaled AZD1402. Part 1 will be performed in a lead-in cohort for each dose level to evaluate the safety and pharmacokinetics (PK) in a population with asthma controlled on medium dose inhaled corticosteroids (ICS)-long acting beta agonists (LABA) before progressing to dosing in adults with asthma who are uncontrolled on medium dose ICS-LABA in Part 2. The study will recruit participants receiving treatment with medium dose ICS with LABA for Part 1 (separate inhalers or combination product) and medium dose ICS-LABA as a combination product for Part 2 at Screening. Part 2 will be initiated for each dose level following evaluation of safety and PK at the relevant dose level in Part 1. The entire study period for each participant in both Parts 1 and 2, is approximately 3.5 months; a 2-week Screening Period, a 4 week Run-in Period, 4 weeks of Treatment Period, and 4 weeks of Follow-Up Period.

NCT04643158
Conditions
  1. Asthma
Interventions
  1. Drug: AZD1402
  2. Drug: Placebo
  3. Drug: Short acting beta agonist (SABA) (rescue medication)
  4. Drug: Run-in medications (ICS-LABA combination)
MeSH:Asthma Respiratory Aspiration
HPO:Asthma

Primary Outcomes

Description: To evaluate the safety and tolerability of AZD1402 compared to placebo at different dose levels in adults with asthma controlled on medium dose ICS-LABA. Safety and tolerability variables included AEs/ adverse events of special interest (AESIs) / serious adverse events (SAEs), vital signs (blood pressure and pulse rate), changes in clinical chemistry, haematology, and coagulation parameters, Immuno-biomarkers, Electrocardiograms (ECGs), Forced expiratory volume in 1 second (FEV1) and fractional exhaled nitric oxide (FeNO).

Measure: Part 1: Number of participants with adverse events (AEs)

Time: From Day 1 until Follow-up (Day 56 ± 4)

Description: To investigate the efficacy of inhaled AZD1402 at different dose levels compared to placebo in adults with asthma who are uncontrolled on medium dose ICS-LABA.

Measure: Part 2: Change from baseline in pre-bronchodilator FEV1 at Week 4

Time: Baseline and Week 4

Secondary Outcomes

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Maximum observed serum (peak) drug concentration (Cmax)

Time: Day 1 until Day 56 ± 4

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Time to reach peak or maximum observed concentration or response following drug administration (tmax)

Time: Day 1 until Day 56 ± 4

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Observed lowest drug concentration reached before the next dose is administered (pre-dose) (Ctrough)

Time: Day 1 until Day 56 ± 4

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Terminal rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (λz)

Time: Day 1 until Day 56 ± 4

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz)

Time: Day 1 until Day 56 ± 4

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)

Time: Day 1 until Day 56 ± 4

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Area under plasma concentration-time curve in the dosing interval (AUCτ)

Time: Day 1 until Day 56 ± 4

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

Time: Day 1 until Day 56 ± 4

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F)

Time: Day 1 until Day 56 ± 4

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Area under the plasma concentration time curve in the dosing interval τ divided by the dose administered (Dose normalised AUCτ)

Time: Day 1 until Day 56 ± 4

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Maximum observed plasma (peak) drug concentration divided by the dose administered (Dose normalised Cmax)

Time: Day 1 until Day 56 ± 4

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Time of last observed (quantifiable) concentration (tlast)

Time: Day 1 until Day 56 ± 4

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Accumulation ratio for AUCτ (Rac AUC)

Time: Day 1 until Day 56 ± 4

Description: To investigate the PK profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants in each treatment arm).

Measure: Part 1 and Part 2: Accumulation ratio for Cmax (Rac Cmax)

Time: Day 1 until Day 56 ± 4

Description: To investigate the immunogenicity of AZD1402.

Measure: Part 1 and Part 2: Antidrug antibodies (ADA) titers testing for all ADA-positive samples as measure of immunogenicity

Time: Day 1 until Day 56 ± 4

Description: To further investigate the efficacy of AZD1402 at different dose levels compared to placebo in adults with asthma who are uncontrolled on medium dose ICS-LABA.

Measure: Part 2: Change from baseline in pre bronchodilator FEV1 average over the 4-week Treatment Period

Time: Baseline, 4 weeks

Description: To further investigate the efficacy of AZD1402 at different dose levels compared to placebo in adults with asthma who are uncontrolled on medium dose ICS-LABA.

Measure: Part 2: Change from baseline in post bronchodilator FEV1 average over the 4-week Treatment Period

Time: Baseline, 4 weeks

Description: To further investigate the efficacy of AZD1402 at different dose levels compared to placebo in adults with asthma who are uncontrolled on medium dose ICS-LABA. The ACQ was developed to measure asthma control. In the ACQ-6, participants will be asked to recall how their asthma has been during the previous week by responding to one bronchodilation use question and 5 symptom questions. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). Higher scores indicated worse outcome. The mean ACQ-6 score is the mean of the responses. Mean scores of ≤ 0.75 indicate well-controlled asthma, scores between 0.75 and ≤ 1.5 indicate partly controlled asthma, and scores > 1.5 indicate not well-controlled asthma. Individual changes of at least 0.5 are considered clinically meaningful.

Measure: Part 2: Change from baseline in Asthma control questionnaire-6 (ACQ-6) at Week 4 and average over the Treatment Period

Time: Baseline, Week 4

Description: To further investigate the efficacy of AZD1402 at different dose levels compared to placebo in adults with asthma who are uncontrolled on medium dose ICS-LABA. The ACQ was developed to measure asthma control. In the ACQ-6, participants will be asked to recall how their asthma has been during the previous week by responding to one bronchodilation use question and 5 symptom questions. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). Higher scores indicated worse outcome. The mean ACQ-6 score is the mean of the responses. Mean scores of ≤ 0.75 indicate well-controlled asthma, scores between 0.75 and ≤ 1.5 indicate partly controlled asthma, and scores > 1.5 indicate not well-controlled asthma. Individual changes of at least 0.5 are considered clinically meaningful.

Measure: Part 2: Proportion of participants with a decrease in ACQ 6 score of ≥ 0.5 from baseline to Week 4

Time: Baseline, Week 4

Description: To further investigate the efficacy of AZD1402 at different dose levels compared to placebo in asthmatics who are uncontrolled on medium dose ICS-LABA. The SGRQ is a 50-item instrument developed to measure the health status of participants with airway obstruction diseases. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The SGRQ yields a total score and 3 domain scores (symptoms, activity, and impacts). The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status. Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater impairment.

Measure: Part 2: Change from baseline in St. George's respiratory questionnaire (SGRQ) score to Week 4

Time: Baseline, Week 4

Description: To further investigate the efficacy of AZD1402 at different dose levels compared to placebo in adults with asthma who are uncontrolled on medium dose ICS-LABA. Peak expiratory flow will be measured by the participant at home using a peak flow meter.

Measure: Part 2: Change from baseline in average morning Peak expiratory flow (PEF) over the Treatment Period

Time: Baseline, 4 weeks

Description: To further investigate the efficacy of AZD1402 at different dose levels compared to placebo in adults with asthma who are uncontrolled on medium dose ICS-LABA. Peak expiratory flow will be measured by the participant at home using a peak flow meter.

Measure: Part 2: Change from baseline in average evening PEF over the Treatment Period

Time: Baseline, 4 weeks

Description: To further investigate the efficacy of AZD1402 at different dose levels compared to placebo in adults with asthma who are uncontrolled on medium dose ICS-LABA. Severity scores for asthma symptoms will be recorded twice daily in the morning and evening and documented in the e-Diary. Asthma symptom scores during night-time and day-time will be assessed by the participant each morning and evening according to the following scoring system: 0: You have no asthma symptoms. You are aware of your asthma symptoms but you can easily tolerate the symptoms. Your asthma is causing you enough discomfort to cause problems with normal activities (or with sleep). You are unable to do your normal activities (or to sleep) because of your asthma. Higher scores indicated worse outcome.

Measure: Part 2: Change from baseline in daily average asthma symptom score (AM/PM) over the Treatment Period

Time: Baseline, 4 weeks

Description: To investigate the effect of AZD1402 compared to placebo on airway inflammation in adults with asthma who are uncontrolled on medium dose ICS-LABA. To investigate the effect of AZD1402 on airway inflammation, the measurement of FeNO will be performed in accordance with ATS/ERS guidelines. Standardised conditions with regard to exhalation flow rate and duration of exhalation will be followed such that plateau definition can be evaluated over a minimum of 3 seconds. The concentration of FeNO will be measured in units of part per billion (ppb).

Measure: Part 2: Change from baseline in fractional exhaled nitric oxide (FeNO) at Week 4 and average over the Treatment Period

Time: Baseline, Week 4

Description: To evaluate the safety and tolerability of AZD1402 compared to placebo in adults with asthma who are uncontrolled on medium dose ICS-LABA. Safety and tolerability variables included AEs/AESIs/SAEs, vital signs (blood pressure and pulse rate), changes in clinical chemistry, haematology, and coagulation parameters, Immuno-biomarkers, ECGs, FEV1 and FeNO.

Measure: Part 2: Number of participants with adverse events (AEs)

Time: From Day 1 until the Follow-up (Day 56 ± 4)

HPO Nodes


Reports

Data processed on December 13, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook